Concierge cardiology · UK
Left atrial appendage occlusion, for the AF patient who cannot take anticoagulation.
A keyhole implant that closes the pouch where more than 90% of AF-related clots form — offered at high-volume UK centres under NICE TA867, by consultant interventional cardiologists, when a DOAC is not safe for you.
Why patients choose us
- 01
A consultant interventional cardiologist, in a proper cath lab
A named implanter at a high-volume UK LAAO centre — not a trainee, not a general list, and the TOE done by a dedicated imaging cardiologist.
- 02
The alternative kept honestly on the table
DOACs remain first-line for most people with AF. We say so plainly before you commit to a device — LAAO is for the bleeding-risk or intolerance subset.
- 03
Independent, and free
We are paid by no clinic, so the recommendation — device, centre, or continuing anticoagulation — is impartial and costs you nothing.
Indicative pricing
What a private LAAO procedure costs in the UK.
Indicative ranges across our partner cardiac centres. Send the details and we quote firm figures across two or three options — or confirm NHS eligibility under NICE TA867.
In short
LAAO with Watchman FLX in our network: £22,000–£28,000, home within 1–2 nights.
| Procedure | Indicative range | Typical duration | Stay |
|---|---|---|---|
| LAAO with Watchman FLX (self-pay) | £22,000–£28,000 | 60–120 min | 1–2 night stay |
| LAAO with Amplatzer Amulet (self-pay) | £23,000–£30,000 | 60–120 min | 1–2 night stay |
| Complex / redo LAAO | £26,000–£32,000 | 90–150 min | 1–2 night stay |
| Pre-procedure TOE + CT LAA | £900–£1,600 | 45–60 min | Same visit |
| 45-day follow-up TOE | £700–£1,200 | 30 min | Same visit |
| Consultant EP / structural review | £300–£500 | 45 min | Same visit |
Prices vary by device, centre, and case complexity, and by whether a CT LAA is added to planning. NHS funding is available at commissioned centres for patients meeting NICE TA867 criteria. We come back with a firm quote within one working day.
The problem
The right patient, the right centre, the right honest alternative.
LAAO is oversold to some patients and under-offered to others. We do the opposite — protect the DOAC-suitable, and press for a device only when the bleeding history really warrants it.
-
On a DOAC and doing well?
You almost certainly do not need LAAO. We will say so, and save you a general anaesthetic you do not need.
-
ICH or repeated major bleeds?
This is where LAAO earns its place. We connect you to a NICE-commissioned centre with a proper MDT.
-
Been told "no" to anticoagulation?
Sometimes rightly, sometimes not. We get a second cardiology opinion before you accept a lifetime of stroke risk.
The journey
From enquiry to the 45-day TOE — what happens, in order.
One coordinator from first message to follow-up echo — including the 45-day check that decides when you step down to aspirin.
Phase 1 · Before your procedure
Concierge, off-stage for you
Phase 2 · On the day
One or two nights on the ward
Phase 3 · After
45-day TOE and step-down
- 01
Before
You tell us what is going on
A short, confidential form. Your AF history, CHA₂DS₂-VASc and HAS-BLED story, any bleeding events, current anticoagulant, and why it is being reconsidered.
- 02
Before
We come back with a recommendation
Within one working day: whether LAAO fits NICE TA867 criteria for you, which UK centre suits, and an indicative price. If continuing a DOAC is safer, we say so.
- 03
Before
Assessment and cardiac MDT
A consultant review, TOE (or CT LAA) to characterise appendage anatomy and size the device, and a cardiac MDT sign-off before a date is offered.
- 04
On the day
Admission for the implant
Admitted the morning of the procedure. General anaesthetic, TOE guidance, femoral vein access — no chest incision. You will stay one to two nights.
- 05
On the day
The procedure itself
60 to 120 minutes in the cath lab. Transseptal puncture into the left atrium, device delivered via sheath, TOE confirms PASS criteria before release.
- 06
On the day
Overnight monitoring
Groin site checked, telemetry overnight, and a next-day echo to exclude pericardial effusion before discharge.
- 07
After
Forty-five-day TOE and step-down
Short-course anticoagulant (or DAPT for Amulet) then a 45-day TOE to confirm endothelialisation and no significant leak — then step down to aspirin.
Typical end-to-end: 4–8 weeks from enquiry to implant. Step down to aspirin: usually at 45 days if the follow-up TOE is clean.
When it helps
When LAAO is the right step.
The NICE TA867 subset — AF plus high stroke risk plus a genuine reason not to take an anticoagulant — with one red flag that is not an elective at all.
-
AF with high stroke risk and bleeding
Non-valvular AF, CHA₂DS₂-VASc ≥2 (men) or ≥3 (women), and a HAS-BLED ≥3 or documented major bleeding on anticoagulation.
-
Intracerebral haemorrhage history
A previous brain bleed on anticoagulation is one of the clearest indications where LAAO is considered instead of a DOAC.
-
Recurrent major GI bleeding
Repeated significant gastrointestinal bleeds on warfarin or a DOAC, when the source cannot be reliably fixed.
-
Severe renal impairment or dialysis
Chronic haemodialysis and severe CKD where DOAC options are limited and warfarin control has been poor or unsafe.
-
Frailty and falls with bleeding
Recurrent falls with head injury and bleeding events, where the balance of stroke prevention and bleeding risk has shifted.
-
Anticoagulant intolerance
Genuine intolerance — not simply preference — where DOACs and warfarin have both been trialled and failed.
-
Planned major surgery
A patient facing repeated procedures requiring anticoagulation interruption, where a device offers a cleaner long-term option.
-
Red flag: acute stroke or active bleed
A new stroke, TIA, or active bleeding is an emergency — same-day A&E, not an elective LAAO booking.
Devices and options
One device does not fit every appendage.
Watchman FLX and Amplatzer Amulet are the two NICE-approved devices in the UK. TOE and CT LAA imaging decide which fits — and whether a device is the right answer at all.
-
Watchman FLX (Boston Scientific)
Nitinol frame with a PET membrane — the most widely used device in the UK, suited to a broad range of oval and variable appendage anatomies.
-
Amplatzer Amulet (Abbott)
A dual-lobe and disc design that suits some anatomies where Watchman does not sit well — with a different post-implant antiplatelet regime.
-
CT LAA planning
Cardiac CT of the appendage — increasingly used alongside TOE to characterise chicken-wing, windsock, cactus or cauliflower morphology and size the device.
-
Transoesophageal echo (TOE)
The workhorse imaging for LAAO — used both to plan the case and to guide the implant, confirming position, anchor, size and seal before release.
-
Intracardiac echo (ICE)
An emerging alternative to TOE at some UK centres — imaging from inside the heart, sometimes avoiding a general anaesthetic.
-
LARIAT (epicardial suture)
A percutaneous epicardial ligation of the appendage — rarely used in the UK and reserved for very specific anatomies where a device is not feasible.
-
Surgical LAA exclusion
Closure of the appendage at the time of cardiac surgery for another indication — a different pathway, discussed if you are already listed for surgery.
-
Continuing anticoagulation
For most people with AF, a DOAC remains the safest option. If that fits you better than a device, we will say so.
Our vetted UK network
High-volume LAAO centres, we picked them.
Consultant interventional cardiologists at commissioned UK structural heart centres. Not listed publicly — introductions are made privately, once we understand your case.
Selection criteria
How we choose every LAAO centre in our network.
-
High-volume UK LAAO centres commissioned under NICE TA867
-
Consultant interventional cardiologists with dedicated structural or EP practice
-
Cardiac MDT sign-off before every implant
-
Dedicated imaging cardiologist for TOE planning and intra-procedural guidance
Safety and recovery
What to expect — honestly.
LAAO is a mature procedure with a well-characterised risk profile — the numbers are small, the imaging follow-up is strict, and the antiplatelet plan afterwards is not a nothing.
-
Pericardial effusion and tamponade
The main procedural risk, quoted at about 1–3%. Occasionally needs percutaneous drainage; very rarely surgical repair.
-
Peri-procedural stroke
Around 1–2%, from either the transseptal puncture and device manipulation or later embolisation. Careful anticoagulation on the table reduces it.
-
Device embolisation
Very rare when sizing and PASS criteria are respected. If it happens, the device is usually retrieved percutaneously.
-
Device-related thrombus (DRT)
Around 3–5% at 12 months, most often in patients stepped down to aspirin only. A short course of anticoagulation usually resolves it.
-
Residual peri-device leak
A leak >5 mm at the 45-day TOE means anticoagulation is continued rather than stopped — the device is not counted as sealed.
-
Vascular access complications
Groin haematoma or pseudoaneurysm from the femoral vein puncture. Usually managed conservatively, occasionally with thrombin injection.
-
Transient AV block and arrhythmia
Uncommon and usually short-lived. Telemetry overnight is standard for this reason.
-
The post-implant drug regime is not "nothing"
Watchman FLX: DOAC or warfarin for 45 days plus aspirin, then aspirin. Amulet: dual antiplatelet 1–6 months, then aspirin. It is a step down, not a stop.
-
Red flags after discharge
New chest pain, breathlessness, one-sided weakness or speech change, or a swollen painful groin — call the centre or A&E the same day.
Reading your implant note
Your implant note in four parts. Read the last one first.
Whichever device was used, the note the interventional cardiologist sends you keeps to the same shape.
A quiet reminder
Structural cardiology language is precise and can read coldly — we translate it for you.
If you would like us to talk you through the note before your 45-day TOE, just ask.
- 01 Header
Indication and MDT decision
Why the appendage was closed — high bleeding risk, ICH history, GI bleeding, dialysis — and the cardiac MDT decision that supported it.
- 02 Technique
Device, size and PASS criteria
The device used (Watchman FLX or Amulet), the size chosen, and how the five PASS criteria — Position, Anchor, Size, Seal — were confirmed on TOE before release.
- 03 Findings
Appendage anatomy and any leak
Appendage morphology (chicken wing, windsock, cactus, cauliflower), landing zone measurements, and any peri-device leak at implant and at 45 days.
- 04 Impression
Post-implant drug plan and follow-up
Read this first: which anticoagulant or antiplatelet for how long, when the 45-day TOE is booked, and when you can step down to aspirin alone.
Recognised by major UK insurers
Insurer cover for LAAO depends on the indication and the specific policy — usually funded when NICE TA867 criteria are met, sometimes self-pay for patients outside the commissioned pathway. We confirm cover before booking.
Frequently asked
Everything we get asked about LAAO.
Quick answers on eligibility, device choice, the procedure day, the drug regime afterwards, and how it compares to a DOAC.
-
What is left atrial appendage occlusion (LAAO) and why is it done?
It is a keyhole procedure to plug the left atrial appendage — the small pouch off the left atrium where more than 90% of AF-related clots form. Physically closing it reduces stroke risk without needing lifelong anticoagulation, for patients who cannot safely take one.
-
Who is LAAO actually for in the UK?
Under NICE TA867 (2023) it is for people with non-valvular AF, a high stroke risk (CHA₂DS₂-VASc ≥2 in men, ≥3 in women), and a genuine contraindication or intolerance to long-term anticoagulation — recurrent major bleeding, previous intracerebral haemorrhage, severe renal impairment, dialysis, or recurrent GI bleeding.
-
Is LAAO better than a DOAC like apixaban or rivaroxaban?
For most people with AF, no — DOACs are first-line and easier. LAAO is comparable to warfarin for stroke prevention in the PROTECT-AF, PREVAIL and EWOLUTION data, with significantly less major bleeding at five years. It is the right answer for the specific subset who cannot tolerate anticoagulation.
-
Watchman FLX or Amplatzer Amulet — which device?
Both are approved by NICE and used across UK centres. Watchman FLX is a single-lobe design suited to a wide range of appendage anatomies. Amulet is a dual-lobe-and-disc design that fits some appendages better and has a different antiplatelet regime afterwards. The choice is anatomy-led and made from the TOE and CT LAA images.
-
What actually happens on the day of the procedure?
Under general anaesthetic with TOE guidance, the cardiologist accesses the femoral vein in the groin, crosses the atrial septum into the left atrium, and delivers the device into the appendage. Once the PASS criteria — Position, Anchor, Size, Seal — are confirmed on echo, the device is released. It takes 60 to 120 minutes and you stay one to two nights.
-
How much does LAAO cost privately in the UK?
Roughly £22,000–£32,000 self-pay depending on device, centre and complexity, including the pre-procedure imaging, implant, one to two nights of care, and the 45-day TOE. NHS funding is available at commissioned centres under NICE TA867 criteria.
-
What are the main risks of LAAO?
Pericardial effusion or tamponade in about 1–3%, peri-procedural stroke in 1–2%, device-related thrombus in 3–5% at 12 months (usually manageable with a short anticoagulation course), rare device embolisation, vascular access issues at the groin, and — very rarely — death. The 45-day TOE is there specifically to catch leaks and thrombus early.
-
Do I still need to take anticoagulation after LAAO?
For a period, yes. Watchman FLX: a DOAC or warfarin plus aspirin for 45 days, then a TOE, then aspirin long-term. Amulet: dual antiplatelet therapy for 1–6 months, then aspirin. If the 45-day TOE shows a leak greater than 5 mm or a device-related thrombus, anticoagulation continues until it is resolved.
-
When should I contact the centre urgently after discharge?
New chest pain or breathlessness, any one-sided weakness, speech change or visual loss, a hot swollen groin, or a fever — these are reasons to call the centre or attend A&E the same day rather than wait for your follow-up.